Name | Title | Contact Details |
---|
Prototypes Warn is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ImprimisRx® is a pharmaceutical company dedicated to delivering high-quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high-quality formulations that are supported by the clinical experience of physicians and their patients. We offer proprietary compounded ophthalmic formulations. All of our innovative drug formulations are born from the clinical experience of physicians and pharmacist formulators. We are focused on people, and believe our unique business model provides us with the opportunity to address unmet patient needs while delivering high quality and affordable medical solutions to physicians and patients.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
Greenway Medical Technologies provides the latest in ambulatory healthcare business solutions and services to 20000 healthcare providers and professionals nationwide, in 30 specialties and subspecialties, by enhancing the delivery of patient care